Intravenous thrombolysis with alteplase is the only approved treatment for acute ischemic stroke, but its efficacy and safety when administered more than 3 hours after the onset of symptoms have ...

Intravenous thrombolysis is a standard treatment of acute ischemic stroke. The efficacy and safety of combining intravenous thrombolysis with argatroban (an anticoagulant agent) or eptifibatide ...

Intravenous thrombolysis in patients hospitalized for cervical artery dissection-related acute ischemic stroke increases the likelihood of home discharge.

A new study published in the Stroke journal revealed a crucial link between early fibrinogen depletion coagulopathy (FDC) and ...

For patients with acute ischemic stroke due to large-vessel occlusion who present within 4.5 hours, intravenous tenecteplase ...

Currently, intravenous thrombolysis is by far the most effective treatment of acute ischemic stroke, and its use can independently strongly increase the proportion of stroke patients surviving.

Stroke patients with dementia treated with intravenous thrombolysis using powerful clot-busting drugs are at no higher risk of brain haemorrhage or death than other patients receiving the same ...

Individuals with STEMI caused by a spontaneous coronary artery dissection (SCAD) who are treated with intravenous thrombolysis prior to coronary angiography fare no worse in the hospital compared with ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

The authors looked at the efficacy and safety of intravenous thrombolysis with alteplase given within three to 4.5 hours after stroke symptom onset. A total of 821 acute stroke patients within ...